Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases.

Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases. Dig Dis Sci. 2019 Mar 05;: Authors: Yarur AJ, Bruss A, Naik S, Beniwal-Patel P, Fox C, Jain A, Berens B, Patel A, Ungaro R, Bahur B, Dubinsky M, Stein DJ Abstract BACKGROUND: The aim of this study was to assess the relationship of serum vedolizumab concentrations (SVC) during induction and endoscopic remission in patients with inflammatory bowel diseases (IBD) after 52 weeks of therapy with vedolizumab. We also sought to assess the incidence of antibody to…

Read More

Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort.

Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort. Inflamm Bowel Dis. 2019 Feb 27;: Authors: Gregory M, Weaver KN, Hoversten P, Hicks SB, Patel D, Ciorba MA, Gutierrez AM, Beniwal-Patel P, Palam S, Syal G, Herfarth HH, Christophi G, Raffals L, Barnes EL, Deepak P Abstract BACKGROUND AND AIMS: Inflammation of the pouch after ileal pouch-anal anastomosis (IPAA) can significantly impact quality of life and be difficult to treat. We assessed the effectiveness and safety of vedolizumab in Crohn’s disease (CD) of…

Read More

Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.

Related Articles Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019 Feb 17;: Authors: Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, Ungaro R, Sy W, Owen SC, Patel A, Cohen BL, Ananthakrishnan AN Abstract BACKGROUND: The older patient group with inflammatory bowel diseases (IBD) is particularly vulnerable to consequences of disease and therapy-related side effects but little is known about the best treatment options in this population. AIM: To compare safety…

Read More

Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.

Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort. J Crohns Colitis. 2019 Feb 14;: Authors: Plevris N, Chuah CS, Allen RM, Arnott ID, Brennan PN, Chaudhary S, Churchhouse AMD, Din S, Donoghue E, Gaya DR, Groome M, Jafferbhoy HM, Jenkinson PW, Lam WL, Lyons M, Macdonald JC, MacMaster M, Mowat C, Naismith GD, Potts LF, Saffouri E, Seenan JP, Sengupta A, Shasi P, Sutherland DI, Todd JA, Veryan J, Watson AJM, Watts DA, Jones GR, Lees CW Abstract INTRODUCTION: Vedolizumab is…

Read More

Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis.

Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis. J Crohns Colitis. 2019 Jan 29;: Authors: Pouillon L, Rousseau H, Busby-Venner H, De Carvalho Bittencourt M, Choukour M, Gauchotte G, Zallot C, Danese S, Baumann C, Peyrin-Biroulet L Abstract Background & Aims: Histological healing may be the ultimate therapeutic goal in ulcerative colitis (UC). We investigated, for the first time, the association between vedolizumab trough levels and histological healing in UC. Methods: This is a single-center retrospective cohort study including all consecutive UC patients on vedolizumab maintenance…

Read More

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation.

Related Articles Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. Aliment Pharmacol Ther. 2019 Jan 20;: Authors: Osterman MT, Rosario M, Lasch K, Barocas M, Wilbur JD, Dirks NL, Gastonguay MR Abstract BACKGROUND: Prospectively designed studies assessing the exposure-response profile of vedolizumab are lacking. Observational exposure-response data for vedolizumab are limited and have not been adjusted for potential confounding factors, particularly those that may affect vedolizumab clearance. AIMS: This analysis aimed to: (a) investigate the vedolizumab exposure-response relationship after adjusting for potential confounding…

Read More

Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease but Not Ulcerative Colitis.

Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease but Not Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 Jan 05;: Authors: Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland B, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV, Sands BE,…

Read More

Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn’s Disease: A Post Hoc Analysis of GEMINI 2 and 3.

Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn’s Disease: A Post Hoc Analysis of GEMINI 2 and 3. Inflamm Bowel Dis. 2019 Jan 04;: Authors: Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T Abstract Background: Combined therapy with vedolizumab and corticosteroids may improve clinical response or remission in Crohn’s disease. The aim of this study is to assess efficacy and safety/tolerability of vedolizumab plus stable doses of corticosteroids at baseline during induction therapy in moderately to severely active Crohn’s disease. Methods: A post…

Read More

Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients.

Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients. J Gastroenterol Hepatol. 2018 Dec 27;: Authors: Van den Berghe N, Verstockt B, Tops S, Ferrante M, Vermeire S, Gils A Abstract BACKGROUND AND AIM: The pivotal GEMINI trials reported low immunogenicity of vedolizumab. However, anti-vedolizumab antibodies (AVA) are frequently underestimated since most assays are not drug-tolerant and unable to detect anti-drug antibodies while there is drug in the circulation. This study aimed to explore which anti-drug antibody assay is best suited to detect AVA…

Read More
<< Go Back